Stocks News

LAST PRICE
31.9800
TODAY'S CHANGE (%)
Trending Down-0.2200 (-0.6832%)

Bid / Lots
31.0400/ 7
Ask / Lots
32.6200/ 2
Open / Previous Close
32.3800 / 32.2000
Day Range
Low 31.5600
High 33.0000
52 Week Range
Low 5.9300
High 38.1200
Volume
475,391
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 22, 2024
- DJ Edgewise Therapeutics Initiated at Outperform by Evercore ISI Group, from 9:53AM ET on Friday Nov 22, 2024 by Dow Jones
  9:53AM ET on Friday Nov 22, 2024 by Dow Jones
  Companies Mentioned: EWTX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/EWTX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 22, 2024 09:53 ET (14:53 GMT)
Nov 8, 2024
- DJ Edgewise Therapeutics Is Maintained at Outperform by Wedbush, from 10:36AM ET on Friday Nov 08, 2024 by Dow Jones
  10:36AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: EWTX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/EWTX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 08, 2024 10:36 ET (15:36 GMT)
- RBC Capital Adjusts Edgewise Therapeutics Price Target to $44 From $42, Maintains Outperform, Speculative Risk Rating, from 9:57AM ET on Friday Nov 08, 2024 by MT Newswires
  9:57AM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: EWTX
  09:57 AM EST, 11/08/2024 (MT Newswires) -- Edgewise Therapeutics (EWTX) has an average rating of Buy and price targets ranging from $33 to $51, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research ...
Nov 7, 2024
- Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
  8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: EWTX
  
  General and Administrative (G&A) expenses were $8.2 million for the third quarter of 2024, compared to $7.4 million for the immediately preceding quarter. The increase of $0.8 million was driven by increased personnel-related costs primarily related to stock-based compensation.
- Press Release: Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
  8:00AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: EWTX

Today
- Xenon to Showcase New Long-Term Azetukalner Data at AES 2024, from 14 hours ago by Dow Jones
  14 hours ago by Dow Jones
  Companies Mentioned: XENE
Nov 22, 2024
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Friday Nov 22, 2024 by Dow Jones
  4:05PM ET on Friday Nov 22, 2024 by Dow Jones
  Companies Mentioned: VERA
Nov 21, 2024
- DJ Vera Therapeutics Initiated at Overweight by Wells Fargo, from 8:14AM ET on Thursday Nov 21, 2024 by Dow Jones
  8:14AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: VERA
Nov 18, 2024
- Press Release: Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer, from 8:00AM ET on Monday Nov 18, 2024 by Dow Jones
  8:00AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: VERA
- Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer, from 8:00AM ET on Monday Nov 18, 2024 by Dow Jones
  8:00AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: VERA
Nov 13, 2024
- DJ Dyne Therapeutics Is Maintained at Buy by Chardan Capital, from 6:43PM ET on Wednesday Nov 13, 2024 by Dow Jones
  6:43PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: DYN
- Xenon to Present at Upcoming Investor Conferences, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: XENE
- DJ Xenon Pharmaceuticals Price Target Maintained With a $53.00/Share by HC Wainwright & Co., from 11:48AM ET on Wednesday Nov 13, 2024 by Dow Jones
  11:48AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: XENE
- DJ Dyne Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co., from 9:45AM ET on Wednesday Nov 13, 2024 by Dow Jones
  9:45AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: DYN
- DJ Xenon Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham, from 6:44AM ET on Wednesday Nov 13, 2024 by Dow Jones
  6:44AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: XENE

Edgewise Therapeutics Inc
NASDAQ:EWTXUnited States

Search Criteria

Nov 22, 2024

DJ Edgewise Therapeutics Initiated at Outperform by Evercore ISI Group, from 9:53AM ET on Friday Nov 22, 2024 by Dow Jones

Nov 8, 2024

DJ Edgewise Therapeutics Is Maintained at Outperform by Wedbush, from 10:36AM ET on Friday Nov 08, 2024 by Dow Jones

RBC Capital Adjusts Edgewise Therapeutics Price Target to $44 From $42, Maintains Outperform, Speculative Risk Rating, from 9:57AM ET on Friday Nov 08, 2024 by MT Newswires

Nov 7, 2024

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones

Press Release: Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights, from 8:00AM ET on Thursday Nov 07, 2024 by Dow Jones

Peers Headlines

Today

Xenon to Showcase New Long-Term Azetukalner Data at AES 2024, from 14 hours ago by Dow Jones

Nov 22, 2024

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Friday Nov 22, 2024 by Dow Jones

Nov 21, 2024

DJ Vera Therapeutics Initiated at Overweight by Wells Fargo, from 8:14AM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 18, 2024

Press Release: Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer, from 8:00AM ET on Monday Nov 18, 2024 by Dow Jones

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer, from 8:00AM ET on Monday Nov 18, 2024 by Dow Jones

Nov 13, 2024

DJ Dyne Therapeutics Is Maintained at Buy by Chardan Capital, from 6:43PM ET on Wednesday Nov 13, 2024 by Dow Jones

Xenon to Present at Upcoming Investor Conferences, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Xenon Pharmaceuticals Price Target Maintained With a $53.00/Share by HC Wainwright & Co., from 11:48AM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Dyne Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co., from 9:45AM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Xenon Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham, from 6:44AM ET on Wednesday Nov 13, 2024 by Dow Jones